Anti-cancer medicine ‘Cyramza’ launched in Bangladesh

Bangladesh-based ealthcare Pharmaceutical Limited and pharmaceutical company Eli Lilly and Company has launched the popular anti-cancer medicine Cyramza in Bangladesh. 

Cyramza is an anti-cancer medicine that is approved as a single agent and/or in combination with other agents for treatment of cancers of the stomach, lungs, liver or intestines that have spread to other parts of the body, said a press release.

The launch event was held at the Intercontinental Hotel in Dhaka with officials of Eli Lilly and Healthcare Pharmaceuticals Limited in attendance on Friday.

Several prominent doctors of the country were also present at the event. 

Luca Visini, managing director of Eli Lilly and Company India, said: “Cancer impacts the lives of many people every year. We are pleased to bring to Bangladesh an option for the first-line treatment of people with metastatic non-small cell lung cancer [NSCLC] and second-line treatment for people living with the burden of gastric cancer.

“We believe this will help us in moving several steps ahead in our collective goal to make lung and gastric cancer a less formidable challenge and a condition that can be managed,” he added.

Bhupati Kumar Roy, executive director (marketing) of Healthcare Pharmaceuticals Ltd, said they are committed to bringing specialized care for people living with chronic conditions, such as diabetes and cancer, to Bangladesh.

Cyramza plus erlotinib is the first and only US FDA-approved anti-VEGFR/EGFR TKI combination therapy for EGFR-mutated metastatic NSCLC.